Replies to post #123890 on Bioelectronics Corp (BIEL)

[Blatcherone]

YOU forgot to mention back pain study almost ready for submission to fda. YOU forgot to mention the 10000 actipatch order, prepaid to Spain not yet reported in earnings. YOU forgot to mention more studies under way or soon to be under way like wound recovery, fracture healing as two examples. How about a stronger device being in the pipeline?
Nhs will increase revenues. Stocking major u.s. retailers is still a question mark. Why are sales not where many think they should be? That question has been answered hundreds of times. Money, money ,money. Dilution can only do so much. They can't spend much on advertising. They are trying to balance all these things with limited funds. Major news to hit nationally could create a buying frenzy that could easily get this to a dime EVEN WITH SHARE STRUCTURE. One guess is as good as another(all things being equal).

[Simpsonly]

My nose tells me BIEL may be experiencing a major surge in sales, with increased momentum to come. I posed the question last week as to whether anyone knows the impact on ActPatch sales in Australia of the 9News TV broadcasting. Wish I knew someone at Mundi or EvoMed in OZ - to me there is no substitute for making retail deals and TV ads.....none. Am I crazy wondering if this quarter could blow the lid off this this....too much silence...

[srinsocal]

"Seriously, what have we done?"

"It has been a year since we last got clearance. What have we done? Seriously, what have we done?"

I am very excited about what BIEL has achieved in the last Year. While I would agree that it has not yet translated into increased sales, as far as we know from the last available Q3 Report, several of the key events have just hit in the last couple of months. The biggest event, NHS Approval, was made public last month but does not kick in until April.

Seriously, this is what we have done:

* Received FDA Clearance for two Indications

* Received FDA OTC Clearance

* Received UK National Health System Coverage for Chronic Pain

* Received US National Distribution through ANDA the US branch of TEVA distribution, 60,000 retail customers

* Hired Keith Nalepka, an experienced, aggressive VP of Sales with industry contacts

* Initiated and completed a 100 patient Back Pain Study, multi billion dollar market

* Meetings with FDA to finalize Full Body FDA Clearance Application

* Initiated Migraine Prevention Study, multi billion dollar market

* Initiated Menstrual Pain Study at Birmingham Women's Hospital, UK NHS Foundation Hospital, multi billion dollar market

* Signed Deal with CARE, 90 member Independent Pharmacy Group for Distribution and Education

* Deal with Mundi Pharma,Distribution in 9 Countries, Mundi is a global distribution network operating in 120 countries

* Deal with Performance Health Distribution, another global company specializing in rehab and sports medicine porducts

* Licensed ActiPatch to PharmEvo, another global company, for Asia sales under the 'Pain Gear' name

* Signed Deal with TESCO, the third largest retailer in the world